Nathan G. Cortez, Nicolas Terry, et al.
August 16, 2017
Len Nichols, Alison E. Cuellar, et al.
August 14, 2017
August 15, 2017
August 10, 2017
August 10, 2017
July 6, 2017
Under a new administration, the FDA is experimenting with a new way to balance innovation and risk with emerging medical technologies.
August 16, 2017 | Health IT
On August 15, CBO and JCT released an analysis of the potential effects of terminating the ACA’s cost-sharing reduction (CSR) payments to insurers. The CBO affirms what earlier analyses have concluded: in the long run the primary loser if CSR payments are terminated would be the federal budget.
A CDC report found that the number of high school students who reported having artificially tanned has decreased by more than half since the enactment of the ACA, from 15.6 percent in 2009 to 7.3 percent in 2015.
If The Trump Administration Terminates Cost-Sharing Reduction Payments, States Can Use 1332 Waivers To Fund Their Own
Creating a State-administered CSR mechanism will undoubtedly require expenditure from the State. While some will argue that the limited resources in State budgets would render the idea all but theoretical, it would be beneficial to examine how States can use Section 1332 to fund CSRs.
It is true that evaluation results of payment reform models so far are not cause for celebration, but there are some positive cost and quality results and lessons are accumulating that can inform the next set of program parameters, incentive structures, and tools to help clinicians succeed.
Philanthropy has awarded important grants for advocacy efforts related to HIV/AIDS—for example, helping to reduce stigma, expand legal services, and inform policy. But that funding is often the only money allocated to advocacy, a powerful weapon in the fight against HIV/AIDS. Advocacy is...
August 11, 2017 | GrantWatch
How does Medicare learn from the current programs to remain focused on improving patient care while maintaining relevance for clinicians and hospitals that are ever-improving their metrics and health care delivery?
The ongoing saga of the cost-sharing reductions just got stranger. On August 10, 2017, the Centers for Medicare and Medicaid Services released at their REGTAP.info website a guidance on risk adjustment methodology and rate filing deadlines.
President Trump’s budget, perhaps the best indication we have of his administration’s priorities, unfortunately appears to show little interest in addressing the social determinants.
The second set of prescription drug briefs tell the story of different prescription drug coverage mechanisms (who pays whom and how much), how they interact with other pricing measures, and what future reforms might look like.
August 10, 2017 | Elsewhere@ Health Affairs